Generize begins offering genetic testing for 338 designated intractable diseases.

Generize Co., Ltd.(Head Office: Chiba University Inohana Innovation Plaza #307, 1-8-15 Inohana,Chuo-ku, Chiba-shi, Chiba; Representative Director: Junichi Hosokawa) launched a genetic testing service specialized for intractable diseases for medical institutions in October 2025. This service achieves both high testing accuracy and operational efficiency in diagnosing intractable diseases through non-invasive specimen collection and advanced analysis technology.

[New Service Supports the Evolution of Genetic Medicine]

In recent years, with the growing importance of personalized medicine, genetic testing has played a crucial role in diagnosing diseases and determining treatment strategies. In Japan, the demand for gene panel tests for companion diagnostics in cancer treatment and the diagnosis of rare diseases is increasing annually. However, challenges such as the complexity of tests, difficulty in interpreting results, and cumbersome application procedures have persisted for both the medical community and patients.

Representative Director Junichi Hosokawa has worked as an internist and has been involved in genetic testing for eight years.

[Features of the Testing Service Combining Advanced Technology andConvenience]

Generize's genetic testing service offers the following features:

1. Reliable Sample Collection

Addressing the Limitations of Blood Samples Conventional genetic testing using blood samples often faces challenges when a sufficient amount of genomic DNA cannot be extracted from patients with decreased white blood cell counts due to chemotherapy or other reasons. The buccal swab collection method used in this service is not affected by blood status and consistently provides the necessary DNA volume from any patient. This is a superior alternative to blood collection, as it reduces patient burden(non-invasive) and lowers the clinical risk of specimen failure.

2. Web-Based Application System

The system is entirely online, moving away from conventional paper-based processes. Medical institutions and users can easily apply for testing via the website, managing everything from application to result confirmation seamlessly.

3. Advanced Analysis Process

Our proprietary technology enables the analysis of genes that are traditionally difficult to sequence.

(1) Support for Hard-to-Analyze Regions (Pseudogenes)

Our unique analysis pipeline enables accurate identification of pseudogenes —which are difficult to analyze with conventional short-read next-generation sequencers (NGS)—even when sequences are highly similar. This allows for the detection of mutations that were previously unidentifiable. 

(2) Multi-layered Bioinformatics Analysis

For the interpretation of detected mutations, we have developed an advanced judgment system integrating three approaches:

-Comprehensive Database Matching: We integrate major national and international disease databases to immediately identify known pathogenic variants.

-Literature-Based Algorithms: We program "pathogenic mechanisms" specific to each gene based on medical papers, evaluating the effects of mutations logically.

-Latest AI Prediction Programs: We employ an evaluation process combining multiple analysis methods to determine not only the presence of mutations but also their clinical significance.

The results of these multi-layered mechanical analyses are finally reviewed by experts to ensure highly accurate reporting.

4. Expert Reports for Informed Decision-Making

Reports include interpretive comments from experts to help clients correctly understand results and make appropriate clinical judgments. We aim to return reports within three weeks to one month fromspecimen receipt.

5. Extensive Test Menu

We offer a menu that meets diverse needs, including panel tests for hereditary intractable diseases (focusing on 338 designated intractable diseases) and hereditary tumors, carrier diagnosis for relatives,and exome analysis for research institutions.

[Company Profile]

Company Name ：Generize Co., Ltd.

Location: Room 307,Inohana Innovation Plaza, Chiba University, 1-8-15, Inohana, Chuo-ku,Chiba-shi, Chiba

Representative Director: Junichi Hosokawa

Establishment ： 2024

Business : Genetesting service, bioinformatics analysis

URL ： https://generize.co.jp

Mail ：support@generize.co.jp

Generize will continue to pursue the improvement of testing technology and user convenience in order to contribute to the development of genetic medicine. Through its genetic testing services for medical and research institutions, Generize will continue to contribute to the realization of personalized medicine and the building of a healthy society.